Brainstorm Cell Therapeutics (STU:GHD) Short Interest


STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
28 GF Score
Price €2.98
! 3 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:GHD vs ADAPY, APRE, JSPR: Short Interest Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Short Interest falls into.


STU:GHD
28GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for STU:GHD

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price